Premium
Anti‐Retroviral Effects of Modified Sodium Silicate (Alkahydroxy/Alka V6)
Author(s) -
Townsend Deana,
White Lauren,
Chesnut Troy,
Duesler Sandra,
Cisneros Ignacio,
Richardson C. Reed,
Vattem Dhiraj
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.537.19
Subject(s) - protease , in vitro , in vivo , reverse transcriptase , chemistry , sodium silicate , sodium , nitric oxide , nuclear chemistry , biochemistry , biology , enzyme , rna , materials science , organic chemistry , microbiology and biotechnology , gene , composite material
Alkahydroxy/Alka V6, a modified sodium silicate dietary supplement manufactured by Cisne Enterprises Inc. (Odessa, TX) was evaluated for its in vitro anti‐retroviral effects. Assays for inhibition of HIV‐II reverse transcriptase (RT), HIV‐II protease (PR) and glucohydrolase (GH) important for viral replication, coat assembly and virulence respectively, were performed using standard kits. Effects on nitric oxide (NO) dependent antiviral activities were measured in neutrophils using standard assays. Chemical structure determined by nuclear magnetic resonance (NMR) and infra‐red (IR) spectroscopy suggested that the product was a mixture of trimeric sodium silicate and sodium silicate pentahydrate. Results suggest that the product the product significantly decreased HIV‐RT activity in a dose dependent manner (ED50 = 16000 ppm). HIV‐PR activity decreased (ED50 = 20000 ppm) with increasing product concentration. The product also decreased the HIV‐II virulence by inhibiting the GH activity (ED50 = 28500 ppm) which decreased protein glucosylation and glucuronylation. Higher NO was detected in neutrophil medium suggesting an increase NO mediated antiviral activity. We conclude the product has anti‐retroviral activity based on in vitro results. In vivo investigations are imperative to determine its overall anti‐retroviral effectiveness. Funding source: Cisne Enterprises Inc.